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ABSTRACT 
A simple, precise, and accurate method was developed for  the estimation of Telmisartan (TEL)  and Chlorthalidone (CHL) in bulk and pharmaceutical dosage 
form  using  first  order  derivative  spectrophotometry.  Wavelength  selected  for  quantitation  were  264.85nm  for  Telmisartan  (zero  crossing  point  of 
Chlorthalidone) and 222.38nm for Chlorthalidone(zero crossing point of Telmisartan). The method was validated with respect to linearity, accuracy, precision, 
limit of detection and limit of quantitation in accordance with the International Conference on Harmonisation (ICH) guidelines. Linearity was observed in 
concentration range of 8-48 µg/ml for Telmisartan and 2.5-15 µg/ml for Chlorthalidone. The limit of detection and limit of quantitation were found to be 
0.234µg/ml and 0.712 µg/ml for Telmisartan and 0.102 µg/ml and 0.309 µg/ml for Chlorthalidone. The percentage recovery of Telmisartan and Chlorthalidone 
was found to be 99.26%  and 99.36%  respectively. The % R.S.D. values for intra-day and inter-day precision study were <1.0%, confirming that the method 
was sufficiently precise. The method can be successfully employed for the simultaneous estimation of Telmisartan and Chlorthalidone in pharmaceutical 
formulations. 
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INTRODUCTION 
Telmisartan(TEL)   is an Angiotensin II receptor antagonist  
used  as  an  antihypertensive  drug.  Chemically  it  is  4′-[[4-
methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-
benzimidazolyl]methyl]-2-biphenylcarboxylic  acid  (Figure 
1)
1,2.Chlorthalidone(CHL) is diuretic drug used in treatment 
of  hyperetension  in  combination  with  Telmisartan.  CHL  is 
chemically  (RS)-2-chloro-5-(1-hydroxy-3oxoisoindolin-l-yl) 
benzenesulphonamide  (Figure2)
1,2.  TEL  and  CHL  both  are 
official in IP
3, BP
4 and USP
5.  TEL is estimated by  Liquid 
Chromatography as per IP
3 and Potentiometric titration as per 
BP
4  and  USP
5.  The  analytical  techniques  reported  for  the 
determination of TEL include HPLC
6-8, spectrophotometry
9-
12, HPTLC
13,14 etc. either separately or in combination with 
other drugs.CHL is estimated by potentiometric titration as 
per IP
3 and  Liquid Chromatography as per BP
4 and USP
5. 
Several analytical method that use liquid chromatography
15-
17, spectrophotometry
19 have  been reported in the literature 
for the determination of CHL in pharmaceutical preparation 
either  separately  or  in  combination  with  other  drugs. 
Literature  survey  does  not  reveal  any  spectrophotometric  
method for simultaneous determination of  TEL and CHL in 
Pharmaceutical dosage form. The present developed method 
is  simple,  precise  and  accurate  for  simultaneous 
determination of both drugs in their Pharmaceutical Dosage 
forms  as  per  International  Conference  on  Harmonization 
(ICH) guidelines
20. 
 
MATERIALS AND METHOD 
Apparatus 
Instrument  used  was  an  UV-VIS-NIR  Spectrometer  Perkin 
Elmer Lambda 19 Range: 185-3200 nm, with a pair of 1 cm 
matched    quartz  cells.  Calibrated  glass  wares  were  used 
throughout the work.   
 
 
 
Reagents and chemicals 
Pure  drug  samples  of  TEL  and  CHL  were  obtained  from 
Alembic Limited, Vadodara, Gujarat. Methanol AR  Grade 
was  used  as  solvent  and  obtained  from  Allied  Chemical 
Corporation, Vadodara, Gujarat, India. 
 
Marketed formulation 
Combined  tablet  formulation  Eritel-  CH40  was  procured 
from local market. Each tablet contains 40 mg Telmisartan 
and 12.5 mg Chlorthalidone. 
 
Preparation of standard stock solution 
Accurately weighed quantity of TEL 10 mg and CHL 10 mg 
was  transferred  into  two  separate  10  ml  volumetric  flask, 
dissolved and diluted up to  mark with methanol.  This will 
give a stock solution having strength of 1000 µg/ml. 
 
Preparation of working standard solution 
5  ml  of  standard  stock  solution  of  TEL  (1000  µg/ml)  and 
CHL(1000 µg/ml) was pipette out in to two separate 50 ml 
volumetric flask and volume was adjusted to the mark with 
methanol to get 100 µg/ml of TEL and 100 µg/ml of CHL. 
 
Determination of wavelength for measurement 
3.2 ml of working standard solution of TEL (100 µg/ml) and 
1.0 ml of working standard solution of CHL(100 µg/ml) was 
pipette  out  in  to  10  ml  volumetric  flask  and  volume  was 
adjusted to the mark with methanol to get 32 µg/ml of TEL 
and 10 µg/ml of CHL. Each solution was scanned between 
200-400 nm.  
The  first  order  derivative  spectra  of  each  solution  were 
obtained. The zero crossing points  were found to be 222.38 
nm and 264.85 nm for TEL and CHL  respectively  (figure  3). 
Wavelengths  selected  for  quantification  were  264.85 nm  
for TEL(zero  crossing  point  for  CHL)  and  222.38  nm  for 
CHL (zero crossing point for TEL). 
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Preparation of calibration curve 
Calibration curve for TEL 
Standard  TEL  solutions  of  8-48µg/ml  were  prepared  by 
pipetting out 0.8, 1.6, 2.4, 3.2, 4.0, 4.8 ml of the working 
standard  solution  of  TEL(100  µg/ml)  into  series  of  10  ml 
volumetric flasks and the volume was adjusted to the mark. 
Absorbance  of  each  solution  was  measured  at  264.85nm  
using    First  order    derivative    spectrophotometry.  A 
calibration curve was prepared by plotting absorbance against 
respective concentration (Figure 4). 
 
Calibration curve for CHL 
Standard  CHL  solutions  of  2.5-15µg/ml  were  prepared  by 
pipetting  out  0.25,  0.5,  0.75,  1, 1.25 and 1.5ml of the 
working standard solution of CHL  (100µg/ml)  into  series  of 
10ml volumetric flasks and the volume was adjusted to mark 
with methanol. Absorbance of each solution was measured at 
222.38 nm  using  First order  derivative  spectrophotometry. 
A  calibration  curve  was  obtained  by  plotting  absorbance 
against respective concentration (Figure 5). 
 
Development and validation of method 
Linearity and range 
Aliquots of working standard solutions of TEL and CHL were 
taken in 10 ml volumetric flasks and diluted with methanol to 
get final concentrations in  range  of  8-48µg/ml  for  TEL and 
of  2.5-15 µg/ml of CHL. This calibration range was  prepared 
six times  and  absorbances  were  measured  at  respective 
wavelengths for each drug separately. 
 
Precision 
Precision  of  the  method  was  determined  by  performing 
interday  variation and   intraday  variation(%RSD). Intra-day 
precision (%RSD) was assessed by analyzing standard drug 
solutions  within  the  calibration  range,  three  times  on  the 
same  day.  Inter-day  precision  (%RSD)  was  assessed  by 
analyzing drug solutions within the calibration range on three 
different days over a period of 7 days. 
   
Repeatability 
For  repeatability  study,  32µg/ml  of  TEL  and  10µg/ml 
concentration of CHL were measured six times. 
 
Recovery studies 
To  study  the  accuracy  of  the  proposed  method,  recovery 
studies were carried out by standard addition method at three 
different  levels(80%, 100%,120%) .  A  known  amount  of 
drug    was    added  to  pre  analyzed    sample    powder    and  
percentage  recoveries  were calculated. 
 
LOD and LOQ 
The LOD and LOQ were calculated by equation. Based on 
the standard deviation of the response and the slope,  LOD 
and LOQ were estimated using the formulae: 
LOD= 3.3 σ/S 
LOQ = 10 σ/S   
 Where, σ = the standard deviation of the response, S = the 
slope of the calibration curve 
LOD and LOQ were determined from the standard deviations 
of the responses for six replicate determinations. 
 
Analysis  of  TEL  and  CHL  in  marketed  Tablet 
Formulation 
To determine the content of TEL and CHL simultaneously in 
conventional tablets (Eritel- CH40 label  claim 40  mg  TEL 
and 12.5 mg CHL); twenty tablets were accurately weighed, 
average  weight  determined  and  ground  to  fine  powder.  A 
quantity of powder equivalent to 40 mg TEL and 12.5 mg 
CHL was transferred into 50 ml volumetric flask containing 
40 ml methanol, sonicated  for 20  min and diluted to mark 
with same solvent to obtain 800 µg/ml of TEL and 250 µg/ml 
of CHL. The resulting solution was filtered using 0.45 μm 
filter (Millifilter, MA). 1ml of the above filtrate was diluted to 
10 ml with methanol to obtain 80 µg/ml of TEL and 25 µg/ml 
of CHL. 2 ml of above solution was further diluted to 10 ml 
with methanol to  obtain 16 µg/ml of TEL and 5 µg/ml of 
CHL. The absorbance of the resulting solution was measured 
using first order  derivative  spectrophotometry at 264.85 nm 
for TEL and  222.38  nm  for  CHL. The  concentration  of  
each drug was calculated using equation of straight line. 
 
Table 1: Result of Calibration readings for TEL 
 
Concentration 
µg/ml 
Absorbance Mean  
(n=6) ± SD 
%RSD 
8  0.09622±0.00062  0.651 
16  0.17271±0.00057  0.329 
24  0.24907±0.00052  0.212 
32  0.32141±0.00073  0.227 
40  0.40121±0.00051  0.128 
48  0.45348±0.00856  0.188 
 
Table 2: Result of Calibration readings for CHL 
 
Concentration 
µg/ml 
Absorbance Mean 
(n=6) ± SD 
%RSD 
2.5  0.06735±0.00057  0.846 
5  0.13637±0.00082  0.605 
7.5  0.19675±0.00064  0.327 
10  0.24852±0.00104  0.419 
12.5  0.31170±0.00061  0.198 
15  0.37125±0.00072  0.195 
 
Table 3: Statistical Data of TEL and CHL 
 
Parameters  Result for TEL  Result for CHL 
Linearity Range(µg/ml)  8-48  2.5-15 
Slope  0.009  0.024 
Intercept  0.027  0.012 
Limit of Detection(µg/ml)  0.234  0.102 
Limit of Quantitation(µg/ml)  0.712  0.309 
Regression Equation  Y=0.009X+0.027  Y=0.024X+0.012 
Co-Efficient of Determination (r
2)  0.997  0.998 
 
Table 4: Intra-Day and Inter-Day study of TEL 
 
Concentration 
(µg/ml) 
Intra-Day Abs. Mean 
(n=3) ± SD 
%RSD  Concentrati-on 
(µg/ml) 
Inter-Day Abs. Mean 
(n=3) ± SD 
%RSD 
16  0.17212±0.0003  0.214  16  0.17184±0.0002  0.120 
24  0.24888±0.0003  0.148  24  0.24872±0.0006  0.276 
32  0.32147±0.0013  0.43  32  0.32207±0.0004  0.132 Parmar Kreny E et al. Int. Res. J. Pharm. 2013, 4 (3) 
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Table 5: Intra-Day and Inter-Day study of CHL 
 
Concentration 
µg/ml 
Intra-Day Abs. Mean 
(n=3) ± SD 
%RSD  Concentration 
µg/ml 
Inter-Day Abs. Mean 
(n=3) ± SD 
%RSD 
5  0.1371±0.0005  0.408  5  0.13642±0.0006  0.488 
7.5  0.19729±0.0006  0.327  7.5  0.19625±0.0007  0.383 
10  0.24837±0.0005  0.229  10  0.24910±0.0004  0.170 
Table 6: Repeatability study of TEL and CHL 
 
Concentration  TEL (32µg/ml)  CHL (10µg/ml) 
Absorbance  0.32137  0.24869 
  0.32278  0.24746 
  0.32135  0.24821 
  0.32118  0.24989 
  0.32056  0.24738 
  0.32125  0.24952 
Mean  0.32141  0.24852 
± SD  0.00073  0.00104 
%RSD  0.227  0.419 
 
Table 7: Determination of Accuracy 
 
Concentration of Sample 
Taken (µg/ml) 
Concentration of Pure API 
spiked (µg/ml) 
Total Concentration  
(µg/ml) 
Mean Total Concentration 
Found (n=3) (µg/ml) 
%Recovery 
Mean (n=3) 
TEL 
16 µg/ml 
12.8  28.8  28.75  99.61 
16  32  31.78  98.63 
19.2  35.2  35.11  99.53 
Avg.                                                                                     99.26 
CHL 
5 µg/ml 
4  9  8.964  99.1 
5  10  9.922  99.44 
6  11  10.972  99.53 
Avg.                                                                                  99.36 
 
Table 8: Assay Result of Marketed Formulation 
 
Parameters  Eritel CH-40 TAB 
  TEL  CHL 
Actual Concentration (µg/ml)  16  5 
Concentration Obtained (µg/ml)  15.88  4.98 
%Purity  99.3  99.73 
%RSD  0.162  0.947 
Limit
3  90-110  92.5-
107.5 
 
 
 
Figure 1: Structure of Telmisartan (TEL) 
 
 
 
Figure 2: Structure of Chlorthalidone (CHL) 
 
 
 
Figure 3: First order derivative overlay of TEL and CHL Parmar Kreny E et al. Int. Res. J. Pharm. 2013, 4 (3) 
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Figure 4: Calibration curve of TEL in Methanol 
 
 
 
Figure 5: Calibration curve of CHL in Methanol 
 
RESULTS AND DISCUSSION 
Validation 
Linearity 
Linear regression data for the calibration plots revealed good 
linear  relationships  between  absorbance    and  concentration 
over  the  ranges  8-48µg/ml  for  TEL  and  2.5-15  µg/ml  for 
CHL.  The linear equations  for the calibration  plots were  y 
=0.009 x+0.027 and  y =0.024x+ 0.012 with Regression(r
2) 
being  0.997  and  0.998  for  TEL  and  CHL,  respectively  
(Figure 3,4,5) (Table 1, 2 and 3). 
 
Precision  
The  precision  of  the  method  was  expressed  as  relative 
standard deviation (RSD %). The %R.S.D. values for intra-
day precision study and inter-day study listed in (Table 4 and 
5) were<1.0%, confirming that the method was sufficiently 
precise. 
 
Repeatability 
The % RSD for absorbance values of TEL and CHL were 
found to be 0.227  and 0.419  respectively, as given in Table 
6. 
 
Accuracy 
When  the  method  was  used  for  accuracy  and  subsequent 
analysis  of  both the drugs  from the  pharmaceutical dosage 
form, and spiked with 80, 100, and 120% of additional pure 
drug, the recovery  was  found to  be 99.26 %  for  TEL  and 
99.36 % for CHL (Table 7). 
 
 
LOD and LOQ 
The LOD and LOQ were calculated by equation. The LOD 
and LOQ values were 0.234 µg/ml and 0.712 µg/ml for TEL 
and 0.102 µg/ml and 0.309 µg/ml for CHL. 
 
Analysis of TEL and CHL in marketed formulation 
When the Eritel CH-40 tablets were analyzed, The % purity 
was  found  to  be  99.3%  for  TEL  and  99.73%  for  CHL. 
(Table 8) 
 
CONCLUSION 
The proposed method was developed for the determination of 
TEL and CHL  in  the  presence  of  each  other.  Methods was  
validated    and    found    to    be    simple,    rapid,    sensitive,  
accurate and precise. The method was  successfully used to 
estimate the amounts of TEL and CHL present in marketed 
tablet formulation containing TEL and CHL. 
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